A study has found that aficamten is associated with improvements across a range of clinical outcomes in patients with obstructive hypertrophic cardiomyopathy.

Rolling Submission of NDA for Aficamten Completed and Submitted to FDA in Q3 COMET-HF, Confirmatory Phase 3 Clinical Trial of ...

View the full release here: "We are honored to be recognized with the Prix Galien Award for Best Digital Health Solution," ...

SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations at the American Heart Association Scientific ...

In a remarkable display of expertise and advanced cardiac care, KMC Hospital, Dr B R Ambedkar Circle successfully treated Fr Wolfgang Leonhard, a 65-year-old German national, who was rushed to the ...

Rohit Bal has been suffering from a cardiac disease known as dilated cardiomyopathy for quite some time. It is a condition in ...

The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy ... and Sisunatovir for respiratory syncytical virus. Receive News & Ratings for ...

The company’s focus has shifted toward upcoming data readouts for sevasemten in Becker muscular dystrophy (BMD) and Duchenne muscular dystrophy (DMD), following positive results for EDG-7500 in ...

As age increases, it becomes important for women to take special care of their health. According to health experts, after the age of 35, eve..|News Track ...

Death is a daunting prospect for many, but after a lot of reflection and work on herself, Bella Salsberry feels at peace with the life she's been granted.

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2024 and recent business highlights.